Workflow
GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GRI BioGRI Bio(US:GRI) Globenewswireยท2025-09-03 13:00

Company Overview - GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through innovative therapies targeting Natural Killer T (NKT) cells [3] - The company's lead program, GRI-0621, is an oral therapeutic aimed at inhibiting iNKT cell activity for the treatment of idiopathic pulmonary fibrosis, addressing a significant unmet medical need [3] - GRI Bio is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [3] Upcoming Events - Marc Hertz, PhD, CEO of GRI Bio, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:00 PM ET in New York, NY [1] - Management will be available for in-person one-on-one meetings with qualified investors registered for the conference [2] - A live webcast of the presentation will be available on the company's website, with a replay archived for 90 days post-event [2]